Paper Details

  1. Home
  2. Paper Details

Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial.

Author: AsciertoPaolo A, Basset-SeguinNicole, DrénoBrigitte, DummerReinhard, DutriauxCaroline, ErnstD Scott, FifeKate, FittipaldoAlberto, GrobJean-Jacques, GuillotBernard, HanssonJohan, HauschildAxel, JouaryThomas, KunstfeldRainer, LicitraLisa, MeyerNicolas, MortierLaurent, ThomasLuc, WilliamsSarah, XynosIoannis

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This article describes the STEVIE study, which was designed to assess the safety of vismodegib, a Hedgehog pathway inhibitor, in patients with advanced basal cell carcinoma. The study aims to gather safety data in a real-world setting with long-term follow-up.
Paper Details　
Original Abstract of the Article :
The Hedgehog pathway inhibitor vismodegib has shown clinical benefit in patients with advanced basal cell carcinoma and is approved for treatment of patients with advanced basal cell carcinoma for whom surgery is inappropriate. STEVIE was designed to assess the safety of vismodegib in a situation si...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/S1470-2045(15)70198-1

データ提供：米国国立医学図書館（NLM）

Vismodegib: A Beacon of Hope for Advanced Basal Cell Carcinoma

The realm of cancer treatment is a vast and challenging desert, where researchers tirelessly search for new weapons against the disease. This study focuses on vismodegib, a Hedgehog pathway inhibitor, and its potential to combat advanced basal cell carcinoma (BCC), a type of skin cancer that can be as formidable as a sandstorm.

The study, like a well-equipped expedition, delves into the effectiveness and safety of vismodegib in a real-world setting, using a large international trial. The researchers are seeking to understand how vismodegib performs in the everyday challenges of clinical practice, like a caravan navigating a diverse and often unpredictable desert landscape.

Vismodegib: A Promising Treatment for Advanced Basal Cell Carcinoma

This study provides encouraging news for patients with advanced BCC, offering hope for effective treatment options. Vismodegib has shown significant clinical benefit in patients for whom surgery is not suitable, offering a lifeline in a potentially challenging situation.

Navigating the Desert of Skin Cancer Treatment

This study highlights the importance of continued research and development in the field of skin cancer treatment. Like a skilled desert guide, researchers are constantly seeking new routes and strategies to combat this challenging disease. Vismodegib represents a significant step forward in the fight against BCC, offering a ray of hope in a potentially dark landscape.

Dr.Camel's Conclusion

This study is a reminder that the desert of cancer treatment is constantly evolving, with new oases of hope emerging on the horizon. Vismodegib stands as a promising treatment option for advanced BCC, offering a potential refuge from the harsh realities of this disease. However, further research is needed to understand the long-term effects of vismodegib and to explore other promising avenues for treating skin cancer.

Date :
  1. Date Completed 2015-08-31
  2. Date Revised 2022-03-31
Further Info :

Pubmed ID

25981813

DOI: Digital Object Identifier

10.1016/S1470-2045(15)70198-1

Related Literature

Article Analysis
・Side Effects of vismodegib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.